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Background: Prognostic factors are associated with the risk of a subsequent outcome in people with a given
disease or health condition. Meta-analysis using individual participant data (IPD), where the raw data are synthesised
from multiple studies, has been championed as the gold-standard for synthesising prognostic factor studies. We
assessed the feasibility and conduct of this approach.
Methods: A systematic review to identify published IPD meta-analyses of prognostic factors studies, followed by
detailed assessment of a random sample of 20 articles published from 2006. Six of these 20 articles were from the
IMPACT (International Mission for Prognosis and Analysis of Clinical Trials in traumatic brain injury) collaboration, for
which additional information was also used from simultaneously published companion papers.
Results: Forty-eight published IPD meta-analyses of prognostic factors were identified up to March 2009. Only three
were published before 2000 but thereafter a median of four articles exist per year, with traumatic brain injury the
most active research field. Availability of IPD offered many advantages, such as checking modelling assumptions;
analysing variables on their continuous scale with the possibility of assessing for non-linear relationships; and
obtaining results adjusted for other variables. However, researchers also faced many challenges, such as large cost
and time required to obtain and clean IPD; unavailable IPD for some studies; different sets of prognostic factors in
each study; and variability in study methods of measurement. The IMPACT initiative is a leading example, and had
generally strong design, methodological and statistical standards. Elsewhere, standards are not always as high and
improvements in the conduct of IPD meta-analyses of prognostic factor studies are often needed; in particular,
continuous variables are often categorised without reason; publication bias and availability bias are rarely examined;
and important methodological details and summary results are often inadequately reported.
Conclusions: IPD meta-analyses of prognostic factors are achievable and offer many advantages, as displayed most
expertly by the IMPACT initiative. However such projects face numerous logistical and methodological obstacles,
and their conduct and reporting can often be substantially improved.
Keywords: Meta-analysis, Prognostic factor, Prognosis, Individual participant (patient) data, Systematic review,
ReportingIntroduction
Prognostic factors are measurable characteristics asso-
ciated with the risk of a subsequent outcome in people
with a given disease or health condition. They include sim-
ple measures such as age or body mass index, and more
complex measures such as biomarkers and genetic factors.
For example, age, glucose levels, motor score and pupillary
reactivity are associated with a higher risk of poor* Correspondence: r.d.riley@bham.ac.uk
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reproduction in any medium, provided the origoutcome in patients with traumatic brain injury [1]. In
breast cancer patients, higher levels of markers uPA and
PAI-1 are associated with a shorter time to disease recur-
rence or death [2]. Prognostic factors have a broad array of
potential uses in both clinical practice and health research
[3]. For instance, they help to define disease at diagnosis
(e.g. cancer diagnosis is usually accompanied by the stage
of disease, based on the prognostic factors of tumour size,
nodal status, and metastasis); they aid the design and ana-
lysis of trials [4]; they are confounders to consider in ob-
servational studies and unbalanced trials [5]; they are theal Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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may even predict treatment response [7].
Primary research studies to identify prognostic factors
are common place in the health and epidemiology litera-
ture. However, meta-analysis of prognostic factor studies
has proven problematic, with most attempted synthesises
only serving to highlight the poor quality of primary
studies and their heterogeneous nature (e.g. in their
choice of cut-off levels, method of measurement, analysis
strategies etc) [8-10]. Even when good quality studies are
available, meta-analysis is usually still halted by difficul-
ties extracting summary data (e.g. hazard ratios and their
confidence intervals) for synthesis [8]. For example, Sut-
cliffe et al.[11] conclude that:
“The considerable variability in results reported within
the prognostic marker categories, the poor quality of
studies and the lack of studies for some categories have
made it difficult to provide clear conclusions as to
which markers might offer the most potential as
prognostic parameters for localised prostate cancer.
These reasons also meant that it was not possible to
quantitatively synthesise the results’.
Meta-analysis using individual participant data (IPD) [12],
where the raw data are obtained from multiple studies and
synthesised, has been championed as a potential solution for
synthesising prognostic factor studies [13-15]. IPD is the ori-
ginal source material and thus, in an ideal situation, offers
numerous potential advantages including [16]: standardizing
statistical analyses in each study; deriving summary prognos-
tic factor results directly, independent of study reporting and
significance; checking modelling assumptions; performing
adjusted analyses in each study with a consistent set of ad-
justment factors; examining non-linear associations and
interactions between prognostic factors; and explaining het-
erogeneity in prognostic factor effects (e.g. across subgroups
of patients, or across studies with different methodological
standards). Altman et al.[17] show in non-small-cell lung
carcinoma that an IPD meta-analysis of prognostic factors
(IMPF) is achievable, and can reveal important findings.
Their meta-analysis of 13 studies is presented in Figure 1
[14], and it shows that microvessel density, when measured
by counting all vessels and analysed as a continuous variable,
is not a prognostic factor for death (summary hazard ratio=
1.03, 95% CI: 0.97 to 1.09), contradicting a previous meta-
analysis of published summary data [18].
However, despite these potential advantages, in reality
the synthesis of IPD may itself have severe problems
[19]. For example, availability of IPD does not overcome
poor quality of primary studies; IPD may not be available
from every study desired; and studies may differ in the
set of prognostic factors (confounders) recorded and
their method of measurement. The IPD approach is alsoknown to be potentially costly and time-consuming [20],
which dissuades many researchers. For example, the IPD
meta-analysis project of Altman et al.[17] was a ‘long, ex-
pensive, and rather laborious process’.
In this article we undertake a systematic review to iden-
tify and then critically appraise published IMPF articles.
The aim is to assess the feasibility of the IMPF approach,
to examine how it is conducted (e.g. how IPD are
obtained, how statistical analyses are performed etc.), to
evaluate how IMPF are reported, and to identify common
challenges facing IMPF projects. By evaluating published
articles, our review findings are clearly dependent on
reporting standards within the articles, and so any appar-
ent research deficiencies identified may merely reflect poor
reporting standards. However, whilst recognising this limi-
tation, our review findings will help inform those currently
embarking upon or contemplating an IMPF, and direct
further methodological research within IPD meta-analysis.
Methods
Inclusion and exclusion criteria
An IMPF article was defined as one which reported, as a
primary objective, a meta-analysis using IPD to assess
the prognostic ability of one (or more) factors in patients
with a specific disease or health condition. A ‘factor’ was
defined as any type of variable that could be measured
quantitatively, and so for example could relate to binary,
categorical or continuous measures. A ‘meta-analysis
using IPD’ was defined as the synthesis of raw patient-
level data across multiple studies or multiple collaborat-
ing groups. There were no restrictions on the type of
prognostic factors, or the disease/health condition under
investigation, or the types of study data (e.g. randomised
trials, observational studies) being synthesised. Articles
focusing on risk factors for disease onset (aetiology) in
healthy individuals, and methodological articles focusing
on methods for conducting an IMPF were excluded.
Articles examining prognostic factors as a secondary ob-
jective were also excluded; for example, studies with a
primary objective to assess a treatment effect were
excluded, even if they adjusted for prognostic factors or
looked at how prognostic factors predicted treatment re-
sponse. Articles with a primary objective to develop a
risk prediction model [21] (i.e. a model that predicts in-
dividual outcome risk using multiple prognostic factors
in combination) were excluded unless a concurrent pri-
mary objective was to assess the prognostic ability of the
individual factors being considered for model inclusion.
Search strategy
It was deemed difficult to search for IMPF articles dir-
ectly, due to the inconsistent nomenclature within prog-
nosis research [22] (e.g. ’predictive’, ’prognostic’; ‘factor’,
‘marker’) and the wide range of potential prognostic
Figure 1 An IPD meta-analysis of whether microvessel density is a prognostic factor for death in patients with non-metastatic
surgically treated non-small-cell lung carcinoma, as undertaken by Trivella et al. [14]. The forest plot shows the individual study hazard
ratio estimates (with confidence intervals), which indicate the association between risk of death and an increase of ten microvessel counts, as
assessed by measurement of all vessels. A random-effects meta-analysis was used to combine estimates (I2 = 73.7%), and the overall hazard ratio
shown is thus the estimated average of all the underlying hazard ratios across studies.
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characteristics, etc). Thus, initially a broader search was
undertaken for any type of IPD meta-analysis article. An
existing database of 199 such articles was already avail-
able from a previous systematic review of the health lit-
erature from 1996 to 2005 [23]. This database was
updated by searching within Medline, Embase and the
Cochrane library from the 1st January 2005 to March 2009
using the same search strategy as used before [23]. We also
crudely searched Google using ’individual patient data meta-
analysis’. The abstracts of all articles identified by the search
were read by the first author and classified in regard their
IPD meta-analysis status as either ’yes’, ’unsure’, or ’no’. The
second author checked all ‘yes’ and ‘unsure’ articles, a ran-
dom 10% of the ‘no’ articles, and any ‘no’ articles that con-
tained ‘individual patient data’ or ‘individual participant data’.
Any discrepancies were resolved by obtaining the full paper.
The abstract of each article classed as an IPD meta-
analysis was then read again and further classed by the
first author as ‘IMPF yes’, ‘IMPF unsure’, and ‘IMPF no’.
The second author checked all these classifications, and
any discrepancy resolved by obtaining the full paper.Finally, the references of ‘IMPF yes’ articles were
checked to identify any relevant articles previously
missed.
Data extraction and in-depth evaluation of recent IMPF
articles
Each article classed as an IMPF was obtained in full and
the following information extracted: year of publication,
location of first author, disease/health condition of partici-
pants, outcomes of interest, and prognostic factors exam-
ined. A more in-depth evaluation was then performed of a
random sample of 20 articles published in or after 2006.
All articles published from 2006 were listed randomly
using computer software, and the first 20 in the list
chosen. Twenty was considered appropriate for pragmatic
reasons (e.g. time) and sufficient for identifying the key
issues, limitations and challenges of IMPF projects; we
were less interested in getting reliable estimates of the
related percentages. A data extraction form was developed
that included 58 questions (available on request). The first
author answered these questions by eliciting the relevant
pieces of information from the full published article; these
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authors, and any discrepancies resolved. The 58 questions
covered the rationale, conduct, analysis, reporting [24,25],
and feasibility of the IMPF project (Table 1). These ques-
tions were part of the protocol for our review, which is
available upon request.Results
Search and classification results
We identified 385 general IPD meta-analysis articles pub-
lished between 1991 and March 2009, including 179 from a
previous IPD database plus 204 from our new searches and
2 from reference checking (Figure 2). Of these, we classed
48 as having a primary objective to assess the prognostic
ability of one or more factors in patients with a defined dis-
ease or health condition. A full list of these references is
available upon request.Overview of the 48 IMPF articles
The 48 IMPF articles consider prognostics factors in a
broad range of diseases and health conditions (Additional
file 1: Figure S1). The most active research area is within
traumatic brain injury, where numerous IPD meta-analyses
have been completed because researchers initiated IM-
PACT (International Mission for Prognosis and Analysis of
Clinical Trials in traumatic brain injury) and shared IPD
from 11 studies (8 randomised trials and 3 observational
studies) including 9205 patients for examining issues related
to heterogeneity between, and prognosis of, patients inTable 1 Summary of the data extraction form involving 58 qu
20 IMPF projects examined in detail
Rationale and
initiation:
We recorded the rationale for the IMPF, and wh
Process of
obtaining IPD:
We recorded how researchers identified relevant
how they decided which studies to seek IPD from
Details of IPD
obtained:
We recorded the proportion of studies providing
participants and events were reported for each IP
was variability in how prognostic factors were m
Type and quality
of IPD studies:
We recorded the design (e.g. cohort, randomised
unpublished; and whether they were assessed fo
Statistical methods
used:
We recorded whether a statistical methods sec
(e.g. Cox regression, logistic regression); and ho
clustering of participants within studies; betwee





We recorded if and how researchers examined th
due to non-significant prognostic results) or availa




As a crude measure of adherence to reporting
we recorded how many of the articles referenc




We catalogued all the problems that hindered
IMPF approach as reported by the researchers.clinical trials [26]. Mortality and disease recurrence were
the two most common outcomes of interest across the 48
articles, with other outcomes tending to be condition-spe-
cific (e.g. Glasgow Outcome Scale score in traumatic brain
injury; middle ear effusion in acute otitis media). Age, sex
and blood pressure were the most common factors exam-
ined for their prognostic ability, again alongside condition-
specific factors (e.g. microvessel density counts in lung can-
cer [14], restrictive mitral filling pattern in cardiovascular
disease [27]).
Only 3 published IMPF articles were identified before
the year 2000 but thereafter a median of 4 articles exist
per year (Figure 3). In 2007 there was a peak of 15 IMPF
articles, due to 8 IMPACT articles [28-35] being pub-
lished simultaneously within the Journal of Neuro-
trauma, with each article generally focusing on a
different class of factors (e.g. demographic, laboratory
variables, coma scale score, etc).In-depth evaluation of 20 recent IMPF articles
Our in-depth evaluation was performed on a random sam-
ple of 20 IMPF articles published from 2006 to 2008 [14,27-
33,36-47]. These included six articles from the IMPACTcol-
laboration [28-33]; when evaluating these articles, we also
utilised information published simultaneously in companion
articles describing the IMPACT study, its design, and statis-
tical analysis plan [4,26,48]. We did this to gain broader
insight into the IMPACT series as a whole, as clearly quality
issues in a single article are dependent on quality issues inestions, which was used to extract information about the
ether there was mention of a project protocol and ethics approval.
primary studies (e.g. systematic review, coalition of research groups);
; the process of obtaining IPD; and problems encountered.
IPD; the total number of participants in the IPD; whether the number of
D study; whether there was any missing data problems; and whether there
easured.
trials) of studies providing IPD; whether they were published or
r their quality and, if so, how.
tion was provided; the statistical models used in the meta-analysis
w some specific statistical issues were addressed (such as
n-study heterogeneity in prognostic factor effects; and the
e potential impact of publication bias (studies unpublished
bility bias (studies providing IPD are a biased portion of the
-analysis.
guidelines for meta-analysis,
ed the reporting guidelines of
the
Figure 2 Details of the search and classification of IMPF articles.
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six IMPACT articles are related, below we typically note if
and how results for the IMPACT project differed to the 14
non-IMPACT articles. We now summarise the key findings
in relation to the eight categories defined in Table 1.
Rationale and initiation
A common rationale for the IMPF projects was to increase
statistical power compared to individual studies alone, andto resolve disagreements in the field; for example, the ration-
ale for Lanterna et al.[45] was that 'emerging evidence sug-
gests that the APOE4 allele may increase the risk of a
negative outcome in patients with aneurysmal subarachnoid
hemorrhage, but the results are conflicting.' Another com-
mon objective was to identify independent prognostic fac-
tors; i.e. those factors with prognostic value even after
adjustment for other standard factors. For example, Trivella
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Year of publication
Figure 3 Number of published IMPF articles over time (NB no articles were identified in 2009 up to the start of March, when our
review was conducted); the spike in 2007 is due to eight articles [28–35] from the IMPACT collaboration being published
simultaneously within the Journal of Neurotrauma.
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other variables including age and stage of disease (Figure 1).
In six of the 20 articles, a concurrent objective was to de-
velop a risk prediction model after the prognostic factors
were identified. The risk prediction model component (e.g.
development [6], application [21], validation [14]) of these
articles is beyond the scope of our evaluations here. Of the
20 articles, fifteen (including the 6 IMPACT articles) men-
tioned that the project was funded. Only 3 articles[27,40,46]
directly stated there was a protocol for the project, and only
1 mentioned they had ethics approval[27]. The IMPACT
articles did not mention ethics approval or a protocol, al-
though the latter can perhaps be inferred by the existence of
separate articles describing the objectives, rationale and ana-
lysis plan for the IMPACT initiative.Process of obtaining IPD
Nine of the 20 IMPF articles used a literature review to
identify primary studies for which IPD was desired
[14,27,37,38,40,43-46]. In the 11 others: the six IMPACT
articles utilised those studies already providing IPD
within the IMPACT database directly [28-33]; one uti-
lised a set of known German trials [42]; one contacted
colleagues in the field who had directed relevant trials
with placebo arms [39]; one identified studies from a re-
cent systematic review and ‘from our files’ [47]; and two
did not state how they identified relevant studies
[36,41].Six of the nine articles using a literature review approach
reported the keywords used for searching, and the most
common databases searched were PubMed, Medline,
Embase, and the Cochrane databases. Once relevant studies
were identified, four of the nine articles explicitly stated
how authors were approached for their IPD (three by e-mail
and one by letter), four simply said authors ‘were asked’, and
one did not mention anything in this regard. Only one of
the nine articles provided a flowchart detailing the process
of searching, classifying, and retrieving IPD studies [37].
Of the 20 articles, eight revealed some resource related
issues for obtaining and managing the IPD, including the
six IMPACT articles. Thakkinstian et al. [37] state that
data cleaning and checking were performed separately
for each study, whilst more strikingly Trivella et al.[14]
state that ‘checking, validation and standardisation of all
datasets took nearly two years’ and ‘for all but three cen-
tres some data corrections were necessary.’ The complex-
ities involved in obtaining and managing IPD in the
IMPACT database are thoroughly described by Mar-
marou et al.[26] who state: ‘the overall process was enor-
mously labour intensive, and required considerable
clinical insight’.Details of IPD obtained
All of the nine IMPF articles using a literature review to
identify relevant studies did not obtain IPD from all studies
desired (Figure 3). Six of these documented why some IPD
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IPD no longer available [46], and lack of resources to par-
ticipate [14]. The percentage of studies providing IPD ran-
ged from 32% to 88%, and five of the nine articles obtained
IPD from 60% or less of the requested studies. The short-
fall appeared larger in those IMPF articles requesting IPD
from 10 or more studies (Figure 4).
All of the 20 articles reported the number of patients
included in their available IPD; this ranged from 131[42] to
8721[33], with a mean and median of 3762 and 2954 re-
spectively. Sixteen of the 20 articles (including five of the six
IMPACT articles) also reported the number of patients sep-
arately for each included IPD study, but only 4 articles
reported the number of outcome events separately for each
IPD study [36,39,45,47]. Though the number of events was
available for each study in the IMPACT database as a whole
[26], the six IMPACTarticles each used a subset of the avail-
able data for which the number of events was not stated.
Missing data was a major problem within the IPD
obtained both at the patient-level and at the study-level.
All 20 IMPF articles reported one or more of: missing
values of prognostic factors and adjustment factors for
some patients within a study (e.g. Rovers et al.[43]);
missing outcome data for some patients within a study
(e.g. Lanterna et al.[45]); and some factors missing com-
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Figure 4 The number of studies for which IPD was requested and obt
to identify relevant studies.Type and quality of IPD studies
The specific design of included IPD studies was well-
documented in the 20 IMPF articles. For example, IM-
PACT articles utilised IPD from three observational stud-
ies and eight randomised trials, from which they
included patients in both placebo and treatment arms
because: ‘as no trial showed a significant difference be-
tween placebo and drug, it was felt that pooling the data
would be appropriate for almost all of the analyses which
are planned to be undertaken.’ In contrast, some authors
(for example Yap et al.[36]) utilised IPD from just the
placebo arm of randomised trials, because the prognosis
of patients in the treatment arm were not of interest
and/or they did not want to model the treatment effect.
For example, Koopman et al. [38] state: ‘To eliminate
possible effects of antibiotic therapy on the findings, we
only included children from the control groups in this
prognostic analysis’. Only 2 of the 20 articles clearly
mentioned that some of their IPD studies were unpub-
lished [14,27]; neither of these was an IMPACT article.
Eight of the 20 articles reported a quality assessment
[49] (or risk of bias [50]) of the studies actually providing
IPD. These included the six IMPACT articles, for which
Marmarou et al.[26] conclude ‘the data within IMPACT is
of as high a standard as can realistically be achieved, as it
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[37] examined the Hardy-Weinberg equilibrium in each
study, and excluded from the subsequent meta-analysis
any study that failed this. Downing et al.[46] state using
quality criteria proposed by McKibbon [51] and Altman
[14], and they note that all four of their IPD studies had
methodological shortcomings. The remaining articles may
have assessed study quality prior to selecting those studies
to request IPD from, but we did not evaluate this.
Statistical methods used
All 20 articles provided a statistical analysis description
in their Methods section.
Statistical models for the patient-level data To analyse
the patient-level data, the most common statistical models
used were Cox regression (6 articles), and either logistic or
proportional odds regression (11 articles, including all 6
IMPACT articles). Nine of the 20 articles (including all six
IMPACT articles) reported checking model assumptions,
in regard either the proportional hazards assumption in
Cox regression or the proportional odds assumption in
odds regression. In eight [27,46] of these nine articles, it
was explicitly stated that model assumptions were checked
separately in each study included in the meta-analysis; for
example, McHugh et al.[48] illustrate how the IMPACT
articles checked the proportional odds assumption in indi-
vidual studies, although they do not report whether this
assumption was met in each study and do not say how
meta-analysis proceeded if the assumption failed in some
studies.
Meta-analysis framework For meta-analysis, nine arti-
cles (including the six IMPACT articles) used only a two-
step approach where the IPD was firstly analysed in each
study separately, and then in the second step the summary
data obtained (e.g. hazard ratios, odds ratios) were synthe-
sised using a traditional model for meta-analysis of aggre-
gate data [52,53]. Ten articles used a one-step approach,
where the IPD across all studies were analysed together
simultaneously. One article used a one-step approach in
some analyses and a two-step approach in others.
Those articles using a two-step meta-analysis framework
naturally account for the clustering of patients within
studies by analysing each study separately in the first step.
However, five of the 11 articles using a one-step method
did not state they adjusted for clustering of patients within
studies; the one-step method requires specific adjustment
for study (e.g. by including a dummy variable for each
study) otherwise it treats the IPD as if all coming from a
single study.
Assessing and accounting for heterogeneity in prognostic
factor effects Between-study heterogeneity in prognosticeffects (e.g. hazard ratios, odds ratios) was examined in
16 of the 20 articles (including all six IMPACT articles),
typically using the I2 statistic [54] or the Q-statistic (chi-
square test for heterogeneity) [55]. Of the 20 articles,
ten (including the six IMPACT articles) specifically
accounted for between-study heterogeneity in their
meta-analysis model by including random-effects; seven
did not account for heterogeneity but justified why, for
example as it was negligible (e.g. Koopman et al.[38]
note small values of I2< 25%) or the chi-square test was
non-significant (e.g. Thakkinstian et al.[37] note the test
gave p> 0.1); two articles did not account for heterogen-
eity in their meta-analysis but did not explain why; and
in the remaining article heterogeneity was examined but
it was unclear whether it was accounted for in the meta-
analysis. Three of the 20 articles [14,45,47] examined
potential causes of between-study heterogeneity; for
example, Trivella et al. [14] perform subgroup analyses
according to the method of measuring microvessel
density.
Analysis of continuous factors Nineteen of the 20 arti-
cles (including all six IMPACT articles) investigated one or
more factors measured on a continuous scale. Of these 19,
eight (including one of the six IMPACT articles) converted
the continuous factors to a categorised scale for the ana-
lysis; five (including two IMPACT articles) analysed the
continuous factors on a continuous scale; and six (includ-
ing three IMPACT articles) used a continuous scale in
some analyses (or for some factors) and a categorised scale
in other analyses (or for other factors). Note that we did
not examine if the handling of continuous factors differed
according to whether they were of primary interest or sec-
ondary interest (e.g. as confounders).
Six of the 11 articles using a continuous scale (including
four of the five IMPACT articles that used a continuous
scale) modelled non-linear trends by using either a spline
function or polynomial terms, and one other article (an
IMPACT article) stated linear trends were most appropri-
ate. Further, in seven of the 11 articles maintaining a con-
tinuous scale, the original continuous scale was changed
for the analysis. For example Goetz et al. [39] divide age in
years by 10, to give the prognostic effect of a 10 year in-
crease in age, whilst Yap et al.[36] log-transform skewed
continuous variables. To aid understanding after non-linear
trends were fitted, the IMPACT articles often reported the
results by comparing groups defined by the 25th and 75th
percentile of the continuous variable. Further, to produce
more interpretable effect estimates, the IMPACT articles
also divided age by 10 years.
Eleven of the 14 articles that used a categorisation justi-
fied their choice of categories. For example, any categorisa-
tion within an IMPACT article was done after inspecting
fitted spline functions for a U-shaped relationship, then
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another article the choice of categorisation appeared due to
statistical significance [42]: ‘Age and percentage of +8 posi-
tive metaphases were included dichotomized as cut-points
were found in the hierarchical cluster analysis at 45 years
(p=0.001) and 80% (p=0.04), respectively.’ The remaining
articles stated choosing categories to make results clinically
meaningful, or choosing cut-points to mirror those used in
previous reports, or having to use cut-off points imposed
on them by the original studies. For example, Rovers et al.
[43] note that ‘some predictor and outcome variables (e.g.
fever and pain) might have been more informative if ana-
lyzed on a continuous scale. Some trials did measure these
items on a continuous scale but, because others did not, we
needed to recode these items as dichotomous variables.’ Ob-
viously, summary meta-analysis estimates for prognostic
factor categories defined as ‘low values’ with ‘high values’
(or ‘low’, ‘middle’, ‘high’) are hard to interpret if different cut-
points are used in the individual studies to define what is a
‘low’ or a ‘high’ value.
Assessment of independent prognostic value Of the
20 articles, 16 (including all 6 IMPACT articles) reported a
multivariable analysis to examine the independent prog-
nostic value of one or more factors after adjusting for
others. Of these 16, seven (including one IMPACT article)
defined the statistical significance criteria by which they
judged a factor to have independent prognostic value. For
instance, in Koopman et al. [38] a criteria of p< 0.05 was
used for statistical significance in the multivariable model
and thus evidence of independent prognostic value. Eleven
of the 16 articles (including all six IMPACT articles)
reported the results in full (i.e. adjusted effect estimate
with uncertainty or p-value) for those factors deemed not
to have independent prognostic value.
Assessment of interactions between prognostic factors
IPD offers the opportunity to examine whether the inter-
action between two or more factors is itself prognostic.
This is rarely considered in primary studies, but IPD
from multiple studies offers improved power for such
assessments. Seven of the 16 articles (including two of
the six IMPACT articles) considered a possible inter-
action between two or more factors in their multivariable
model. For example, in their IMPACT article McHugh
et al. [33] considered whether the interaction between
hypoxia and hypotension is prognostic for 6-month out-
come in patients with traumatic brain injury.
Assessment of potential biases
Publication bias Of the 20 articles, only 2 articles (both
non IMPACT articles) undertook a formal assessment of
whether publication bias or small study effects (i.e. thetendency for small studies in the meta-analysis to give
more favourable prognostic effects than the larger stud-
ies) may be affecting their meta-analysis. Lanterna et al.
[45] assessed the presence of publication bias using a
funnel plot (odds ratios on the x axis and trial size on
the y axis) and Egger’s test for asymmetry [56]. In the
other article [40] the authors state: ‘The present result
may be subject to publication bias. However, inspection of
the funnel plot of the individual hazard ratios for each
included study failed to identify important heterogeneity
(I2 = 0.042, P = 0.06)’; their choice of method here con-
fuses us, as presence of heterogeneity does not imply
funnel plot asymmetry or publication bias.
Availability bias The six IMPACT articles [28-33] uti-
lised IPD from 11 studies, including eight trials. How-
ever, Maas et al. [4] list 21 relevant trials in the field, and
so 13 trials did not provide their IPD, either because
investigators refused to collaborate (potentially because
their trial was not yet published) or because IPD were no
longer retrievable. Despite this, the threat of bias in the
IPD available for the IMPACT database was considered
low, as Marmarou et al.[26] note that ‘part of the
requirements for ABIC (the American Brain Injury Con-
sortium) and EBIC (the European Brain Injury Consor-
tium) when taking on a TBI study is that the data should
ultimately be made available for use in academic projects
such as IMPACT.’ Furthermore, the provision of a trial’s
IPD was unlikely to be associated with the significance of
its prognostic factor results, as the assessment of prog-
nostic factors was not the original aim of any trial.
Of the remaining 14 articles: two obtained IPD from
all desired studies, two did not report their success rate,
and 10 did not obtain IPD from all desired studies. Four
[27,40,45,46] of these latter ten articles reported the
number of patients in the non-IPD studies, but only one
reported the number of events in the non-IPD studies.
Only three [37,43,46] of the 10 articles considered the
robustness of their conclusions to the inclusion/exclu-
sion of the non-IPD studies (availability bias). For ex-
ample, Rovers et al. [43] state ‘6 of the 10 relevant
randomized trials were included in our meta-analysis.
The main-effect results for the 4 trials whose individual
patient data were not available were very similar to those
for the included trials . . . therefore, it is not expected that
inclusion of these data would have changed the results of
this meta-analysis.’ However, similarity in main effects of
treatment comparisons does not imply that the effects of
prognostic factors are not affected. In Thakkinstian et al.
[37] the authors use reported summary data in the non-
IPD studies to partially reconstruct the unavailable IPD
[23,57]; they then combine the fully available IPD with
this reconstructed IPD in logistic regression models, and
show that findings remain statistically non-significant.
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Only two [27,40] of the 20 articles mentioned using
reporting guidelines, with both referring to the MOOSE
guidelines [24].
Limitations and challenges of an IMPF
We elicited numerous challenges of an IMPF that were
mentioned in one or more of the 20 IMPF articles. These
are summarised in Table 2, and include issues withTable 2 Challenges facing researchers conducting an IMPF
Identifying all relevant studies
• Unavailability of IPD in some studies
• Time-consuming and costly nature of obtaining, cleaning and analysing
Issues within individual studies
• Dealing with skewed continuous variables and possible outliers.
• Inability of IPD to overcome deficiencies of original studies, such as bein
multivariable analysis, missing important confounders, missing participa
• How to assess the quality of studies identified
• Re-analysing individual study IPD before considering meta-analysis. For
factor studies see Holländer and Sauerbrei [9]. The re-analysis of a single
influenced by and has consequences for the meta-analysis strategy (15)
Heterogeneity between studies
• Different definitions of disease or outcome; e.g. Noordzij et al.[44] note
MeRGE [40] collaborators note the definition of acute myocardial infarct
• Different participant inclusion and exclusion criteria
• Different methods of measuring the same prognostic factor, for exampl
• For survival data different lengths of follow-up
• Factors measured at different points in time or at different stages of dis
timing of echocardiography was variable in their included studies, altho
• Different (or out-dated) treatments strategies, especially when a mixture
large proportion of the patients in their included trials did not receive c
inhibitor.
• Insufficent information about treatment for some of the studies.
Statistical issues for meta-analysis
• Missing data, including: missing factor values and outcome data for som
• Inability to adjust prognostic effects for a consistent set of adjustment f
• Different measurement techniques between studies may be acceptable
• Insufficient information to separate patient outcomes more discretely, e
nephropathy from graft rejection or acute rejection from chronic rejecti
• Imposed choice of cut-off levels when individual studies categorise the
their provided IPD
• Difficulty in using a continuous scale for continuous factors in meta-ana
do not (e.g. see Rovers et al. [43])
• Considering whether it is sensible and/or possible to investigate differe
• Potential for study-level confounding when assessing whether study co
• Difficulty of interpreting summary meta-analysis results in the presence
Assessment of potential biases
• Potential for publication bias and availability bias
• How to assess the robustness of IPD meta-analysis results to the inclusio
combine IPD studies with summary data studiesidentifying relevant studies and obtaining IPD; dealing with
specific (analysis) issues within the individual studies; deal-
ing with heterogeneity across studies; and the choice of
meta-analysis method. The three most common problems
were unavailability of IPD for some studies, missing data,
and different methods of measuring and recording (prog-
nostic) factors across studies. Eighteen of the 20 IMPF arti-
cles explained how missing data was handled, which
included one or more of : restricting analyses to thosethe IPD.
g retrospective rather than prospective, being too small for a
nt data or being of low methodological quality, etc.
a summary of important issues for the analysis of single prognostic
study as the preliminary or first step toward a meta-analysis is
.
different definitions of hypocalcemia across studies, whilst the
ion changed over time.
e see difficulties described by Look et al [2].
ease across studies; e.g. the MeRGE [40] collaborators note that the
ugh within 2 weeks of the index acute myocardial infarction
of older and newer studies are combined; e.g. Yap et al. [36] state that a
ommon post-myocardial infarction therapy such as β-blockers and ACE
e participants within a study, and unavailable factors in some studies
actors in each study
for adjustment variables, but are critical for the variable of main interest
.g. Thakkinstian et al. [37] could not separate chronic allograft
on
ir continuous variables and/or categorise their continuous outcomes in
lysis when some studies give IPD values on a continuous cale and others
ntial prognostic effects in subgroups
variates (e.g. year of publication) modify the prognostic effect.
of heterogeneity (and heterogeneous populations) across studies.
n/exclusion of studies only providing summary data; and how to
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outcome; assessing only those factors recorded in every
study; and imputation of missing participant-level values
for factors and outcome using a statistical method such as
multiple imputation. The IMPACT articles often imputed
any missing outcomes and missing prognostic factors using
an imputation approach.
For the main factors of interest, seven articles had the
different methods of measurement problem , and three
of these tried to limit this. For example, Trivella et al.
[14] perform a subgroup analyses for each of two meth-
ods (Chalkley vs all vessels) used to count the factor
microvessel density. However, they note that even when
the same counting method was used to count microves-
sel density, individual laboratories still used very different
procedures for measurement of microvessel density. The
other four articles did not attempt to tackle the problem
but still presented summary results that thus represented
some average prognostic effect across all measurement
scales. One of these, Thakkinstian et al.[37], notes this
limitation: ‘since the IPD meta-analysis is a retrospective
collaboration, it is difficult to get clinical variables that
have been assessed and measured using similar methods
across all studies; standardization is best done as a pro-
spective collaboration.’
Discussion
Our review found 48 IMPF articles, which shows an IPD
synthesis of prognostic factors is achievable, and the ap-
proach has become more popular since the year 2000.
This should encourage researchers interested in the
IPD approach, such as Broeze et al.[58] who raise aware-
ness of the benefits of IPD but state that ‘to our know-
ledge, no IPD meta-analyses of diagnostic or prognostic
research have been conducted so far’.
The IMPACT initiative is a leading light in the field,
contributing eight of the 48 articles with generally strong
design, methodological and statistical standards through-
out; it should be a first calling point for researchers
wishing to undertake a similar project. The IMPACT and
other IPD projects identified reflect researchers’ increas-
ing awareness that a meta-analysis of aggregate data
from observational studies is problematic and unreliable
[59], as well documented for some time in the epidemio-
logical literature [15,60]. However, our in-depth assess-
ment of 20 recent IMPF articles identified that the IPD
approach itself has many challenges, with numerous lo-
gistical and methodological issues to consider, as sum-
marised in Table 2. There are also areas where the
conduct and reporting of IMPF projects can be
improved. Obviously, for prognostic factors it is a long
way from single studies to an evidence based assessment
in meta-analyses [61]. The key findings of our review,
and its limitations, are now discussed further, and inTable 3 we outline some key issues for researchers to
consider when planning and undertaking an IMPF.
Limitations of our review
To identify IMPF articles we used a systematic review
that involved a broad search strategy to identify general
IPD meta-analysis articles, followed by their classification
as an IMPF or not. Although we searched four of the lar-
gest electronic databases for relevant articles, other data-
bases do exist, and so it is possible some additional
IMPF articles may exist. We also only checked about
10% of those articles classed as ‘not an IPD meta-ana-
lysis’ by the first author, although Figure 1 shows that
the first author’s initial classifications tended to be cau-
tious (i.e. overly inclusive rather than exclusive). How-
ever, we believe that the main messages from our review
(that IMPF projects are achievable but face many meth-
odological and practical challenges) are unlikely to be
altered by any missing IMPF articles, or that only 20 of
the 48 articles were evaluated in full.
Another limitation is that the information extracted
from the 20 recent IMPF articles is dependent on report-
ing standards therein, and so apparent deficiencies
within an IMPF project may be confounded by poor
reporting. For example, only 3 IMPF articles referred to
a protocol for their project, but this does not necessarily
mean a protocol did not exist in the other 17 articles.
Thus apparent gaps in study conduct may simply relate
to gaps in study reporting. This is particular important
given we only elicited information directly available in
the published IMPF article, and did not utilise other
reports (e.g. protocols, statistical analysis plan) or contact
authors for information directly.
How should an IMPF be initiated?
Our review revealed two competing approaches to initiating
an IMPF: perform a (systematic) literature review and seek
IPD from relevant studies identified, or set-up a collabora-
tive group of selected researchers who agree to share their
IPD. It is difficult to recommend one approach over the
other, and the main aim – for example, to investigate one
or two specific factors, or to investigate many factors simul-
taneously as in IMPACT - also has an important influence
on possible approaches. The systematic review approach is
potentially more thorough, as it seeks to identify and utilise
all existing evidence, but it is also more resource intensive
[14] as large effort is required to identify relevant studies, li-
aise with study authors, and then obtain and clean IPD pro-
vided. Further, at the end of the process IPD is often not
obtained from all identified studies anyway (Figure 4). The
collaborative group approach is thus appealing, as it is
quicker and uses IPD immediately available from collabora-
tors, but one concern is that studies within the collabor-
ation may be a biased selection of the existing evidence (see
Table 3 Important considerations for those planning and undertaking an IMPF project
Rationale & Initiation
• Produce a protocol for the IMPF project prior to its initiation (detailing all aspects of rationale, conduct and statistical analysis) and reference this
upon publication of the IMPF
• Consider whether ethics approval is necessary for the IMPF project, and report this upon publication
Process of obtaining IPD
• Report how primary study authors were approached to obtain their IPD
• Report the strategy used for searching the literature for relevant studies (if relevant), including keywords used and databases searched.
• Provide a flowchart showing the search strategy, classification of identified articles, and retrieval of IPD from relevant studies (where relevant)
• Consider how to improve retrieval of IPD from unpublished studies
Details of IPD obtained
• Report number of participants and events for each included study
• Report a summary of the missing data for each study
• Report the reasons why IPD was unavailable for some studies (if relevant), and if possible, report the number of participants, number of events
and summary prognostic factor results in such studies
Type and quality of IPD obtained
• Consider and report the quality of studies for which IPD were obtained; in particular, are they all of comparable quality?
Statistical methods used
• Check and report the assumptions of the statistical models used; in particular, do model assumptions appear valid in each study separately?
• Where possible, analyse continuous factors on their continuous scale and consider non-linear trends. Univariate analyses are a good starting point,
but a multivariable analysis adjusting for ‘standard’ factors is required to assess the added prognostic value of a factor over ‘established’ factors.
• In multivariable analyses consider carefully which variables can and should be used for adjustment. Sensitivity analyses should be conducted. In a
similar way consider how treatment differences can be handled in the analysis.
• In multivariable analyses, define the criteria used to decide whether a factor has independent prognostic value over other factors; also potentially
consider whether the interaction between two (or more) prognostic factors is important
• Consider a re-analysis of the IPD in each study as a first or preliminary step toward meta-analysis, to better appreciate the issues within each study
first.
• In the meta-analysis, account for clustering of participants within studies (and do not merge IPD and analyse as if IPD all came from a single
study) and report how this was done.
• Measure and, if necessary, account for between study heterogeneity in the prognostic factor effect(s) of interest when undertaking meta-analysis
• Where sufficient studies are available (e.g. 10 per covariate of interest) and heterogeneity of estimated effects of interest exists, examine the
potential causes of such heterogeneity.
• Consider a sensitivity analysis to assess whether meta-analysis conclusions change when restricting to IPD from the higher quality studies (if
relevant)
Assessment of publication bias and availability bias
• Consider the potential impact of publication bias and availability bias on IPD meta-analysis results; in particular, are studies providing IPD
comparable to those studies not providing IPD (if relevant)?
Reporting guidelines
• Utilise reporting guidelines for meta-analysis, such as those for MOOSE [24] and IPD meta-analysis [16]
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‘well-defined’ or inclusive, and not select collaborators (or
datasets) based on significance of their prognostic factor
results. There are at least two possible strategies to help
overcome this dilemma. The first is a collaboratively pre-
planned IPD meta-analysis as discussed in the context of
observational studies in epidemiology over a decade ago
[15]. The second is to seek IPD from only a ‘well-defined’
list of studies, for example only those containing patients in
a particular country of interest, or those using the same
method of measurement for a particular factor.Trivella et al. [14] have a good framework that utilises
both a literature review and a collaborative group approach;
they state that they ‘produced a list of potential partici-
pants—i.e. individuals and centres worldwide who were
researching lung cancer—by doing a thorough literature
search and by getting in touch with professional contacts of
members of the steering committee to obtain details of un-
published studies’. This approach ultimately led to 18 studies
providing IPD, the joint largest number of studies in any of
the IMPF projects examined, though at the expense of two
years to collate, manage, and clean the IPD obtained [16].
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Many aspects of the conduct and reporting of IMPF pro-
jects are done well. For example, all of the 20 articles we
assessed provided a statistical methods section in their
Methods; all 20 reported the total number of participants
within their IPD; 15 of the 20 accounted for heterogen-
eity in prognostic factor effects or justified why not; and
16 of the 20 considered the independent prognostic im-
portance using a multivariable model. However, the
available data from individual studies impose several
challenges to derive a sensible summary estimate from
an IMPF (Table 2) and we also indentified a number of
ways IMPF projects can be improved. Table 3 sum-
marises important considerations when conducting and
reporting IMPF projects.
In particular, it was a surprise that protocols and ethics
approval for IMPF projects were rarely mentioned. Pro-
tocols are essential components of any research project
and enhance its credibility, so they should be made and
referred to. In terms of ethics, researchers may have not
considered this to be relevant if IPD was being used for
the same objectives as in the original studies, for which
ethical approval may exist. For an IMPF project it will be
difficult or even impossible to do more than collecting
and reporting the situation in each study. The chairper-
son from the original study may be asked to contact her
or his ethics committee for approval to provide IPD data.
Reporting standards in general must be improved
within IMPF. Basic information was often missing, such
the number of participants and events within each study
providing IPD, and the keywords used to search for rele-
vant studies. Researchers are encouraged to consider re-
cent guidelines for reporting an IPD meta-analysis [16],
which supplement existing reporting guidelines for
meta-analysis of a non-IPD approach [24,62]. Of course,
an improved reporting of primary studies according to
the REMARK guidelines [63] is also needed, and this
would be most helpful for several steps toward the IMPF
project (e.g. examining study relevance according to in-
clusion/exclusion criteria; identifying outcomes consid-
ered and their specific definition; details about available
variables and measurement techniques).
In terms of statistical analysis, some IMPF projects chose
to analyse continuous factors on a categorised scale with-
out good reason. This approach has severe disadvantages
as it loses statistical power and weakens the ability to assess
non-linear prognostic factors effects [5]. When continuous
factors are presented categorised within the available IPD
itself, we question whether a summary meta-analysis result
is even sensible if different cutpoints are used across stud-
ies.[59] Another issue is that in five articles the meta-ana-
lysis method did not appear to account for clustering of
participants within studies, and thus treated the IPD as if
all coming from a single study, which is not appropriate.Further, four articles did not consider potential between-
study heterogeneity in prognostic factor effects, even
though heterogeneity is one of the most pertinent consid-
erations in any meta-analysis. Researchers should refer to
statistical articles describing how to undertake IPD meta-
analyses that account for clustering and heterogeneity, for
example [53,57,64-66], and to articles describing how ana-
lyse prognostic factors, such as [5,59,61,67].
Another critical issue for is properly acknowledging
the heterogeneity of patient populations, treatment of
the patients, and the available ‘standard’ prognostic vari-
ables used to adjust the effect of the factor of interest in
each study. Issues of the heterogeneity concerning pa-
tient populations and treatment may be tackled by ex-
cluding subgroups of the patients from some of the
single studies, by stratifying analyses or by restricting
analyses to more homogeneous subgroups. Ideally the
same adjustment variables should be used in each study,
but one will be restricted by those available in the IPD
provided and sometimes relevant factors may be missing,
which should be clearly noted. For example, Thakkins-
tian et al.[37] note that they ‘could adjust for only a few
clinical factors . . . Other factors (e.g. immunosuppressive
drugs and dosage, viral hepatitis infection, duration of
dialysis, etc.) that were previously associated with poor
outcomes after renal transplantation were not available
in the datasets obtained.’
Where between-study heterogeneity in a prognostic fac-
tor’s effect is identified in the meta-analysis, researchers
should consider reporting a prediction interval for the po-
tential effect in an individual setting [68]. Currently, fol-
lowing a random-effects meta-analysis, researchers usually
focus on the average prognostic effect estimate and its
confidence interval. However, due to the heterogeneity,
the prognostic effect may be very different to the average
effect in a particular population, and this can be quantified
by the prediction interval [69].
Perhaps most importantly, publication bias and availability
bias were rarely considered in the 20 IMPF articles exam-
ined. These problems are crucial to consider, as they may
cause the IPD available to be a biased (non-random) portion
of a potential prognostic factor’s evidence base [13,19,70].
Publication bias is a well-known concern in meta-analysis,
and is likely to be an even greater problem for prognosis
studies than for therapeutic trials [22]. In the past prognosis
studies have hardly ever been registered, do not have a
protocol or pre-defined analysis plan, and generally have
poor reporting standards, which all increase the threat of
negative findings remaining unpublished [8,10,71]. Having
IPD from prognostic factor studies does not negate the fact
that additional unknown, unpublished studies may also exist
[19,70]. Funnel plots and tests for asymmetry (‘small-study
effects’) are useful tools for identifying potential publication
bias [72], but these were only used in two of the 20 articles.
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ples such as IMPACT, where studies were selected based on
the availability of particular factors and relevant endpoints,
rather than on reported significance of any prognostic fac-
tors. In particular, the IMPACT articles included IPD from
eight randomised trials, for which prognostic factors were
recorded but not of primary interest to the original research-
ers, and so the request and provision of IPD was independ-
ent to knowledge of prognostic factor effects.
Availability bias is an added concern for IPD meta-ana-
lysis, and relates to when not all known studies provide
their IPD [70]. For example, IPD may be less obtainable
from smaller studies and/or studies with non-significant
findings as they are more likely to have lost or destroyed
their IPD. In such situations, comparison of the sum-
mary results in IPD and non-IPD studies is useful to see
if they are similar, as done by Rovers et al.[43] and Thak-
kinstian et al.[37].
Conclusion
In this article we have found that IPD meta-analyses of
prognostic factor studies are achievable and, by using a
sample of recent articles, we have examined how they
are initiated, conducted, analysed and reported. Our
findings reveal how current standards can be improved;
show that the IMPACT initiative is a leading example for
others to follow; expose the potential logistical and meth-
odological challenges facing IMPF projects (Table 2); and
identify important considerations for ongoing and future
IMPF projects (Table 3). Although new methodological re-
search may help limit some of these problems, a prospect-
ively planned IPD meta-analysis – where researchers agree
at the onset of their studies to facilitate an IPD meta-ana-
lysis – is the ideal way forward [15]. We agree with
McShane et al.[73] who state that for prognostic factor re-
search ‘the necessity of large, definitive prospective studies
or prospectively planned meta-analyses . . . must be
recognized.’
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